2795-LB: Increased Confidence and Behavioral Adaptation: Exploring Dexcom CGM Use during Ramadan in People with Diabetes

Le résumé fourni par la source

Introduction and Objective: Ramadan is an important religious observance for many people with diabetes and involves altered eating patterns, medication timing, and self-management routines that may influence glycemic outcomes and confidence in fasting. This retrospective study evaluated perceived value, confidence, and behavioral impact associated with Dexcom CGM use during Ramadan in adults with T1D or T2D. Methods: Dexcom CGM metrics and survey responses were analyzed for adults with glucose data during Ramadan 2025 across select countries in Arab Gulf, Jordan, and Lebanon. Analyses were stratified by diabetes type, T2D insulin use, and perceived impact of CGM on fasting. Between-group differences were assessed. Results: Sample included 141 T1D, 10 T2D insulin, and 47 T2D no insulin participants. In all therapy groups, 80% or more reported increased confidence managing diabetes during Ramadan with CGM and were likely to recommend CGM to others fasting. Medication dose/timing adjustment was the most frequently reported behavior change (25%). Participants reporting increased confidence with CGM showed higher TIR 70-180 mg/dL (71 ± 23 vs 54 ± 25 %, p<0.05) and higher CGM wear time (76 ± 30 vs 57 ± 34 %, p=0.1) vs those not reporting increased confidence. Among T2D participants, Ramadan self-management patterns differed by therapy. Insulin users more frequently reported medication adjustments, increased glucose monitoring, reduced physical activity, and food choice changes vs non-insulin users (all p <0.05), suggesting distinct adaptation approaches. Conclusion: To our knowledge, this is among the first real-world analyses to characterize behavioral responses and perceived value associated with CGM use during Ramadan. Dexcom CGM supported greater confidence and meaningful behavior adaptation during fasting. These findings provide actionable evidence for clinicians to use CGM-informed behavioral insights to personalize support for safe Ramadan participation across diverse diabetes populations. Disclosure M. Crawford: Employee; Current; Dexcom, Inc. C. Hicks: Employee; Current; Dexcom, Inc. H. Yousri: None. R. Alamoudi: None. M.M. Hassanein: None. T. Eren: Employee; Current; Dexcom, Inc. N. Gopisetty: Employee; Current; Dexcom, Inc. C. Chen: Employee; Current; Dexcom, Inc., Google. C.L. Griffen: Employee; Current; Dexcom, Inc. M.E. Al-Sofiani: Speaker's Bureau; Ended; Medtronic, Dexcom, Inc. Research Support; Current; Dexcom, Inc. Research Support; Ended; Medtronic. Speaker's Bureau; Ended; Insulet Corporation, Abbott Diabetes, Sanofi. H. Singh: Employee; Current; Dexcom, Inc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.